PMC

*All cumulative incidence functions for ESRD account for competing risk of death.
(a) Cumulative incidence function for survival to ESRD after renal biopsy in those with IFTA vs. no IFTA. (b) Cumulative incidence function for survival to ESRD after renal biopsy in those with moderate/severe IFTA vs. none/mild IFTA. (c) Cumulative incidence function for survival to ESRD after renal biopsy among those with Class III/IV nephritis, in those with moderate/severe IFTA vs. none/mild IFTA. (d) Cumulative incidence function for survival to ESRD after renal biopsy in those with Class III/IV nephritis vs. no Class III/IV nephritis. (e) Cumulative incidence function for survival to ESRD after renal biopsy in those with vascular injury vs. no vascular injury. (f) Cumulative incidence function for survival to ESRD after renal biopsy in those with moderate/severe vascular injury vs. none/mild vascular injury. (g) Cumulative incidence function for survival to ESRD after renal biopsy among those with Class III/IV nephritis, in those with moderate/severe vascular injury vs. none/mild vascular injury.

Combined Effect of Baseline CLIN-PATH Risk Score and rs1800450 Genotype in Predicting ESRD at 5-year (A) or 10-year (B) after Renal Biopsy. ^*P < 0.05. CLIN-PATH risk score was calculated based on equations from Xie J's study (). (A) Predicting ESRD at 5-years, comparing to GG group with ESRD risk <1%, patients with GA and ESRD risk <1% had a 1.02-fold higher risk (95% CI, 0.28–3.78) of ESRD, patients with AA and ESRD risk <1% had a 5.1-fold higher risk (95% CI, 0.65–40.46) of ESRD, patients with GG and ESRD risk ≥1% had a 6.4-fold higher risk (95% CI, 3.20–12.91) of ESRD; patients with GA and ESRD risk ≥1% had a 8.7-fold higher risk (95% CI, 4.14–18.40) of ESRD; patients with AA and ESRD risk ≥1% had a 25.4-fold higher risk (95% CI, 7.76–83.01) of ESRD; (B) Predicting ESRD at 10 years, comparing to GG group with ESRD risk <1%, patients with GA and ESRD risk <1% had a 1.7-fold higher risk (95% CI, 0.15–18.49) of ESRD, patients with AA and ESRD risk <1% had a 0.001-fold higher risk of ESRD, patients with GG and ESRD risk ≥1% had a 9.9-fold higher risk (95% CI, 2.42–40.24) of ESRD; patients with GA and ESRD risk ≥1% had a 12.7-fold higher risk (95% CI, 3.05–53.11) of ESRD; patients with AA and ESRD risk ≥1% had a 37.1-fold higher risk (95% CI, 7.17–192.13) of ESRD.

ESRD = end-stage renal disease.

Incidence of ESRD and death by CKD stage. (Left panel) Competing risk of ESRD (competing event: death before ESRD) and (right panel) death before ESRD (competing event: ESRD) in patients stratified for CKD stages. Tables indicate the numbers of patients at risk (those who did not have ESRD or those who died).